Arcus Biosciences (RCUS) Revenue (2017 - 2026)

Arcus Biosciences' Revenue history runs 10 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• On a quarterly basis, Revenue fell 39.29% year-over-year to $17.0 million in Q1 2026; TTM through Mar 2026 was $236.0 million, a 67.38% increase from a year earlier, with the FY2025 full-year figure at $247.0 million, down 4.26% from the prior year.
• Revenue fell to $17.0 million in Q1 2026 per RCUS's latest filing, from $33.0 million in the prior quarter.
• Across five years, Revenue topped out at $160.0 million in Q2 2025 and bottomed at $14.0 million in Q4 2023.
• The 5-year median for Revenue is $29.0 million (2023), against an average of $43.2 million.
• Across the five-year window, Revenue slumped 90.41% in 2022 and soared 480.0% in 2024, its largest moves.
• Year by year, Revenue stood at $34.0 million in 2022, then slumped by 58.82% to $14.0 million in 2023, then surged by 85.71% to $26.0 million in 2024, then gained by 26.92% to $33.0 million in 2025, then slumped by 48.48% to $17.0 million in 2026.
• Per Business Quant, the three latest RCUS Revenue figures stand at $17.0 million (Q1 2026), $33.0 million (Q4 2025), and $26.0 million (Q3 2025).